FDA Approves New Interchangeable Biosimilar to Pertuzumab By Ogkologos - December 3, 2025 37 0 Facebook Twitter Google+ Pinterest WhatsApp Approval is based on comparisons across a broad range of structural and functional product quality attributes Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Real-World Patients with Cancer Show Lower Survival Times and Treatment-Associated Survival... March 18, 2025 HER2-Low Expression Identified in Half of Solid Tumour Samples Tested for... September 13, 2023 Breast Cancer Survivor Earned Yoga Instructor Certification During Chemo. Now She... May 8, 2019 Robust and Sustained Survival Benefit with Consolidation Durvalumab After Concurrent Chemoradiotherapy... February 8, 2022 Load more HOT NEWS FDA Approves Crizotinib for Children and Young Adults with Relapsed or... Trastuzumab May Improve Survival in Women with Rare Endometrial Cancer Woman Suffers Seizure And Dies After Making Fatal Error With Her... Molecular Determinantion of Outcomes in a Study with Pembrolizumab for Advanced...
